Recon: FDA approves Eyenovia’s pupil-dilating spray; Baxter to sell biopharma business for $4.25B
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy